4DMedical (ASX:4DX) has taken a significant step in the commercial rollout of its flagship CT:VQ technology. It announced that Stanford University has become the first US Academic Medical Centre to adopt the platform under a commercial agreement, less than two months after receiving clearance from the US Food and Drug Administration.
The deal with Stanford’s 3D Quantitative Imaging Laboratory (3DQ Lab) builds on an existing relationship. It will allow for up to 20,000 CT scan analyses annually across 4DMedical’s suite of respiratory imaging solutions, including CT LVAS and IQ-UIP. The addition of CT:VQ under a pay-per-scan model will provide access to reimbursement pathways, accelerating clinical adoption and evidence generation in a live clinical environment.
Stanford’s commercial deployment marks the first step in 4DMedical’s strategy to establish a network of key opinion leader sites across major US academic medical centres. These sites will act as anchors for physician education, clinical validation, and market adoption, positioning CT:VQ as a contrast-free, workflow-integrated alternative to nuclear medicine VQ scans. The technology delivers higher resolution imaging and improved patient access, setting the stage for a new standard of care in pulmonary imaging.
In parallel, 4DMedical and AstraZeneca are expanding their lung health screening program in Brazil, adding five hospitals to the initiative launched earlier this year at Hospital Madre Teresa in Belo Horizonte. The expansion, including four hospitals in São Paulo and one in Joinville, Santa Catarina, will enable approximately 38,000 additional CT scans each year. The program uses 4DMedical’s imaging analytics to detect lung cancer and incidental findings such as coronary artery calcification and early-stage COPD.
4DMedical MD and CEO Andreas Fouras said the developments reflect strong momentum post-FDA clearance. "Our partnership with AstraZeneca continues to gain exceptional momentum. The expansion of the Brazilian Lung Health Screening Program to five additional hospitals, within just weeks of launch, demonstrates both the scalability of our platform and its growing importance in large-scale population health initiatives," Fouras said.
"Stanford's transition to a full commercial CT:VQ contract, less than two months after FDA clearance, represents a powerful validation of our go-to-market strategy. As a globally respected leader in clinical innovation and lung imaging, Stanford serves as an ideal anchor for our CT:VQ commercialisation approach: establishing a network of opinion-leading sites across key US AMCs to accelerate awareness, adoption, and confidence in CT:VQ as the new standard of care in pulmonary imaging. We are immensely proud to have Stanford as the first AMC to implement CT:VQ following FDA clearance."